Adverse events: 1. death: at end of treatment · emotionalism after stroke
Pharmaceutical interventions showed no clear difference in adverse events: 1. death: at end of treatment compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events between 0 and 16 weeks · predominantly knee osteoarthritis
Antidepressant showed no clear difference in serious adverse events between 0 and 16 weeks compared with placebo (low certainty).
1 finding from 1 review
Any adverse events (excluding major bleeding) · people with cerebral small vessel disease and no dementia
1 finding from 1 review
Any adverse events (excluding major bleeding) · s with mixed prevalence of antiplatelet drug use at baseline, for the prevention of cognitive decline and dementia in people with cerebral…
1 finding from 1 review
Tolerability ‐ total number of adverse events · adults with long‐term physical conditions (18 years or older)
1 finding from 1 review
Number of participants experiencing any serious adverse events · Children with obstructive sleep apnoea (aged 15 years or younger)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events within 48 hours post operation · women undergoing PPTL under local anaesthesia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Adverse events within 48 hours post operation · women undergoing PPTL under local anaesthesia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Adverse events within 48 hours post operation · women undergoing PPTL under local anaesthesia
It is very uncertain whether lidocaine instillation changes adverse events within 48 hours post operation compared with placebo (very low certainty).
1 finding from 1 review
RR 1.04 [0.4, 2.69]
Studies not reported
Very low
Adverse events within 48 hours post operation · women undergoing PPTL under local anaesthesia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Serious adverse events: cardiovascular events · dialysis vascular access outcomes in AVG patients with ESKD
It is very uncertain whether omega‐3 fatty acids changes serious adverse events: cardiovascular events compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events: cardiovascular events · Dialysis vascular access outcomes in AVF patients with ESKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: psychological disorders · adults with chronic neuropathic pain
1 finding from 1 review
Serious adverse events assessed using ICH‐GCP
It is very uncertain whether L‐ornithine L aspartate changes serious adverse events assessed using ICH‐GCP compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Adverse events associated with transfusion · People with a haematological disorder
1 finding from 1 review
Adverse events Adverse events per participant · people with spasticity following stroke
It is very uncertain whether systemic antispasticity drugs changes adverse events Adverse events per participant compared with placebo (very low certainty).
1 finding from 1 review
Number of participants with any adverse events · primary progressive multiple sclerosis
Ocrelizumab probably leads to higher number of participants with any adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events during the study period · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review
Serious adverse events during the study period · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in serious adverse events during the study period compared with placebo or standard of care alone (moderate certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · Children with obstructive sleep apnoea (aged 15 years or younger)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found